Statistics for Amylyx Pharmaceuticals, (id:7594 AMLX)

Valuation metrics

Market cap

482.28M

Enterprise value

195.91M

Trailing P/E (ttm)

2.54

Forward P/E

-3.37

PEG ratio

-3.37

Price/Sales (ttm)

2.45

Price/Book (mrq)

2.18

Enterprise Value/Revenue

1.00

Enterprise Value/EBITDA

-0.79

Overview

Shares outstanding

68.55M

Float

42.22M

Shares short

1.01M

% Held by insiders

0.14%

% Held by institutions

0.94%

Average volume (10 days)

1.45M

Average volume (90 days)

Price summary

52-Week low

1.58

52-Week high

19.95

52-Week change

-145.35%

Beta

-0.70

50-Day moving average

3.86

200-Day moving average

4.61

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

-132.05%

Operating margin

-18,187.74%

Operational effectiveness

Return on assets

-43.44%

Return on equity

-84.43%

Income statement

Revenue (ttm)

2.89

Revenue per share (ttm)

2.89

Quarterly revenue growth (yoy)

Gross profit (ttm)

355.34M

EBITDA

39.89M

Net income to common (ttm)

-259,466,000.00

Diluted EPS (ttm)

-3.39

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

234.40M

Total cash per share (mrq)

3.42

Total debt (mrq)

2.57M

Total Debt/Equity (mrq)

1.31

Current ratio (mrq)

454.90%

Book value per share (mrq)

2.86

Cash flow

Cash flow statement

-95,088,000.00

Levered free cash flow (LFCF)

-78,903,504.00